IBDEI07M ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10005,1,2,0)
 ;;=2^Retrobulbar Inj,Medication
 ;;^UTILITY(U,$J,358.3,10005,1,3,0)
 ;;=3^67500
 ;;^UTILITY(U,$J,358.3,10006,0)
 ;;=67505^^71^685^9^^^^1
 ;;^UTILITY(U,$J,358.3,10006,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10006,1,2,0)
 ;;=2^Retrobulbar Inj,Alcohol
 ;;^UTILITY(U,$J,358.3,10006,1,3,0)
 ;;=3^67505
 ;;^UTILITY(U,$J,358.3,10007,0)
 ;;=68200^^71^685^13^^^^1
 ;;^UTILITY(U,$J,358.3,10007,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10007,1,2,0)
 ;;=2^Subconjunctival Injection
 ;;^UTILITY(U,$J,358.3,10007,1,3,0)
 ;;=3^68200
 ;;^UTILITY(U,$J,358.3,10008,0)
 ;;=96372^^71^685^11^^^^1
 ;;^UTILITY(U,$J,358.3,10008,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10008,1,2,0)
 ;;=2^SC/IM Injection
 ;;^UTILITY(U,$J,358.3,10008,1,3,0)
 ;;=3^96372
 ;;^UTILITY(U,$J,358.3,10009,0)
 ;;=96402^^71^685^12^^^^1
 ;;^UTILITY(U,$J,358.3,10009,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10009,1,2,0)
 ;;=2^SQ/IM Anti-Neplastic Hormone Inj
 ;;^UTILITY(U,$J,358.3,10009,1,3,0)
 ;;=3^96402
 ;;^UTILITY(U,$J,358.3,10010,0)
 ;;=C9257^^71^685^2^^^^1
 ;;^UTILITY(U,$J,358.3,10010,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10010,1,2,0)
 ;;=2^Bevacizumab Inj 0.25mg
 ;;^UTILITY(U,$J,358.3,10010,1,3,0)
 ;;=3^C9257
 ;;^UTILITY(U,$J,358.3,10011,0)
 ;;=J1094^^71^685^4^^^^1
 ;;^UTILITY(U,$J,358.3,10011,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10011,1,2,0)
 ;;=2^Dexamethasone Acetate Inj per 1mg
 ;;^UTILITY(U,$J,358.3,10011,1,3,0)
 ;;=3^J1094
 ;;^UTILITY(U,$J,358.3,10012,0)
 ;;=J2778^^71^685^8^^^^1
 ;;^UTILITY(U,$J,358.3,10012,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10012,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,10012,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,10013,0)
 ;;=J3300^^71^685^14^^^^1
 ;;^UTILITY(U,$J,358.3,10013,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10013,1,2,0)
 ;;=2^Triescence Inj per 1mg
 ;;^UTILITY(U,$J,358.3,10013,1,3,0)
 ;;=3^J3300
 ;;^UTILITY(U,$J,358.3,10014,0)
 ;;=J3301^^71^685^7^^^^1
 ;;^UTILITY(U,$J,358.3,10014,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10014,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,10014,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,10015,0)
 ;;=J3396^^71^685^15^^^^1
 ;;^UTILITY(U,$J,358.3,10015,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10015,1,2,0)
 ;;=2^Verteporfin Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,10015,1,3,0)
 ;;=3^J3396
 ;;^UTILITY(U,$J,358.3,10016,0)
 ;;=J9035^^71^685^3^^^^1
 ;;^UTILITY(U,$J,358.3,10016,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10016,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,10016,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,10017,0)
 ;;=J0178^^71^685^1^^^^1
 ;;^UTILITY(U,$J,358.3,10017,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10017,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,10017,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,10018,0)
 ;;=67028^^71^686^1^^^^1
 ;;^UTILITY(U,$J,358.3,10018,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10018,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,10018,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,10019,0)
 ;;=J9035^^71^686^3^^^^1
 ;;^UTILITY(U,$J,358.3,10019,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10019,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,10019,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,10020,0)
 ;;=J2778^^71^686^5^^^^1
 ;;^UTILITY(U,$J,358.3,10020,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10020,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,10020,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,10021,0)
 ;;=J3301^^71^686^4^^^^1
 ;;^UTILITY(U,$J,358.3,10021,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10021,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,10021,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,10022,0)
 ;;=J0178^^71^686^2^^^^1
 ;;^UTILITY(U,$J,358.3,10022,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10022,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,10022,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,10023,0)
 ;;=4450F^^71^687^2^^^^1
 ;;^UTILITY(U,$J,358.3,10023,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10023,1,2,0)
 ;;=2^Self-Care Ed Provided to Pt
 ;;^UTILITY(U,$J,358.3,10023,1,3,0)
 ;;=3^4450F
 ;;^UTILITY(U,$J,358.3,10024,0)
 ;;=4177F^^71^687^3^^^^1
 ;;^UTILITY(U,$J,358.3,10024,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10024,1,2,0)
 ;;=2^Talk Pt/Crgvr Re AREDS
 ;;^UTILITY(U,$J,358.3,10024,1,3,0)
 ;;=3^4177F
 ;;^UTILITY(U,$J,358.3,10025,0)
 ;;=4174F^^71^687^1^^^^1
 ;;^UTILITY(U,$J,358.3,10025,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10025,1,2,0)
 ;;=2^Couns Potent Glauc Impct
 ;;^UTILITY(U,$J,358.3,10025,1,3,0)
 ;;=3^4174F
 ;;^UTILITY(U,$J,358.3,10026,0)
 ;;=373.32^^72^688^48
 ;;^UTILITY(U,$J,358.3,10026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10026,1,3,0)
 ;;=3^Eyelid,Dermatitis,Allergic
 ;;^UTILITY(U,$J,358.3,10026,1,4,0)
 ;;=4^373.32
 ;;^UTILITY(U,$J,358.3,10026,2)
 ;;=^269061
 ;;^UTILITY(U,$J,358.3,10027,0)
 ;;=373.00^^72^688^4
 ;;^UTILITY(U,$J,358.3,10027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10027,1,3,0)
 ;;=3^Blepharitis
 ;;^UTILITY(U,$J,358.3,10027,1,4,0)
 ;;=4^373.00
 ;;^UTILITY(U,$J,358.3,10027,2)
 ;;=Blepharitis^15271
 ;;^UTILITY(U,$J,358.3,10028,0)
 ;;=373.2^^72^688^7
 ;;^UTILITY(U,$J,358.3,10028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10028,1,3,0)
 ;;=3^Chalazion
 ;;^UTILITY(U,$J,358.3,10028,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,10028,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,10029,0)
 ;;=374.84^^72^688^29
 ;;^UTILITY(U,$J,358.3,10029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10029,1,3,0)
 ;;=3^Eyelid Cysts
 ;;^UTILITY(U,$J,358.3,10029,1,4,0)
 ;;=4^374.84
 ;;^UTILITY(U,$J,358.3,10029,2)
 ;;=^269119
 ;;^UTILITY(U,$J,358.3,10030,0)
 ;;=374.87^^72^688^31
 ;;^UTILITY(U,$J,358.3,10030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10030,1,3,0)
 ;;=3^Eyelid Dermatochalasis
 ;;^UTILITY(U,$J,358.3,10030,1,4,0)
 ;;=4^374.87
 ;;^UTILITY(U,$J,358.3,10030,2)
 ;;=^269123
 ;;^UTILITY(U,$J,358.3,10031,0)
 ;;=375.15^^72^688^12
 ;;^UTILITY(U,$J,358.3,10031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10031,1,3,0)
 ;;=3^Dry Eye Syndrome
 ;;^UTILITY(U,$J,358.3,10031,1,4,0)
 ;;=4^375.15
 ;;^UTILITY(U,$J,358.3,10031,2)
 ;;=Dry Eye Syndrome^37168
 ;;^UTILITY(U,$J,358.3,10032,0)
 ;;=374.01^^72^688^20
 ;;^UTILITY(U,$J,358.3,10032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10032,1,3,0)
 ;;=3^Entropion, Senile
 ;;^UTILITY(U,$J,358.3,10032,1,4,0)
 ;;=4^374.01
 ;;^UTILITY(U,$J,358.3,10032,2)
 ;;=Entropion, Senile^269074
 ;;^UTILITY(U,$J,358.3,10033,0)
 ;;=375.20^^72^688^68
 ;;^UTILITY(U,$J,358.3,10033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10033,1,3,0)
 ;;=3^Lacrimal,Epiphora
 ;;^UTILITY(U,$J,358.3,10033,1,4,0)
 ;;=4^375.20
 ;;^UTILITY(U,$J,358.3,10033,2)
 ;;=Epiphora^269136
 ;;^UTILITY(U,$J,358.3,10034,0)
 ;;=373.11^^72^688^63
 ;;^UTILITY(U,$J,358.3,10034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10034,1,3,0)
 ;;=3^Hordeolum Externum
 ;;^UTILITY(U,$J,358.3,10034,1,4,0)
 ;;=4^373.11
 ;;^UTILITY(U,$J,358.3,10034,2)
 ;;=^58510
 ;;^UTILITY(U,$J,358.3,10035,0)
 ;;=373.12^^72^688^64
 ;;^UTILITY(U,$J,358.3,10035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10035,1,3,0)
 ;;=3^Hordeolum Internum
 ;;^UTILITY(U,$J,358.3,10035,1,4,0)
 ;;=4^373.12
 ;;^UTILITY(U,$J,358.3,10035,2)
 ;;=^58512
 ;;^UTILITY(U,$J,358.3,10036,0)
 ;;=216.1^^72^688^54
 ;;^UTILITY(U,$J,358.3,10036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10036,1,3,0)
 ;;=3^Eyelid/Canthus,Benign Neopl
 ;;^UTILITY(U,$J,358.3,10036,1,4,0)
 ;;=4^216.1
 ;;^UTILITY(U,$J,358.3,10036,2)
 ;;=Neoplasm, Benign of Lid^267630
 ;;^UTILITY(U,$J,358.3,10037,0)
 ;;=374.30^^72^688^43
 ;;^UTILITY(U,$J,358.3,10037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10037,1,3,0)
 ;;=3^Eyelid Ptosis,Unspec
 ;;^UTILITY(U,$J,358.3,10037,1,4,0)
 ;;=4^374.30
 ;;^UTILITY(U,$J,358.3,10037,2)
 ;;=^15283
 ;;^UTILITY(U,$J,358.3,10038,0)
 ;;=375.30^^72^688^9
 ;;^UTILITY(U,$J,358.3,10038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10038,1,3,0)
 ;;=3^Dacryocystitis
 ;;^UTILITY(U,$J,358.3,10038,1,4,0)
 ;;=4^375.30
 ;;^UTILITY(U,$J,358.3,10038,2)
 ;;=Dacrocystitis^30880
 ;;^UTILITY(U,$J,358.3,10039,0)
 ;;=921.1^^72^688^28
 ;;^UTILITY(U,$J,358.3,10039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10039,1,3,0)
 ;;=3^Eyelid Contusion
 ;;^UTILITY(U,$J,358.3,10039,1,4,0)
 ;;=4^921.1
 ;;^UTILITY(U,$J,358.3,10039,2)
 ;;=^275367
 ;;^UTILITY(U,$J,358.3,10040,0)
 ;;=374.51^^72^688^46
 ;;^UTILITY(U,$J,358.3,10040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10040,1,3,0)
 ;;=3^Eyelid Xanthelasma
 ;;^UTILITY(U,$J,358.3,10040,1,4,0)
 ;;=4^374.51
 ;;^UTILITY(U,$J,358.3,10040,2)
 ;;=^269107
 ;;^UTILITY(U,$J,358.3,10041,0)
 ;;=374.11^^72^688^15
 ;;^UTILITY(U,$J,358.3,10041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10041,1,3,0)
 ;;=3^Ectropion, Senile
 ;;^UTILITY(U,$J,358.3,10041,1,4,0)
 ;;=4^374.11
 ;;^UTILITY(U,$J,358.3,10041,2)
 ;;=Ectropion, Senile^269083
 ;;^UTILITY(U,$J,358.3,10042,0)
 ;;=333.81^^72^688^6
 ;;^UTILITY(U,$J,358.3,10042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10042,1,3,0)
 ;;=3^Blepharospasm
 ;;^UTILITY(U,$J,358.3,10042,1,4,0)
 ;;=4^333.81
 ;;^UTILITY(U,$J,358.3,10042,2)
 ;;=Blepharospasm^15293
 ;;^UTILITY(U,$J,358.3,10043,0)
 ;;=351.8^^72^688^62
 ;;^UTILITY(U,$J,358.3,10043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10043,1,3,0)
 ;;=3^Hemifacial Spasm
 ;;^UTILITY(U,$J,358.3,10043,1,4,0)
 ;;=4^351.8
 ;;^UTILITY(U,$J,358.3,10043,2)
 ;;=Hemifacial Spasm^87589
 ;;^UTILITY(U,$J,358.3,10044,0)
 ;;=374.10^^72^688^17
 ;;^UTILITY(U,$J,358.3,10044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10044,1,3,0)
 ;;=3^Ectropion, Unspecified
 ;;^UTILITY(U,$J,358.3,10044,1,4,0)
 ;;=4^374.10
 ;;^UTILITY(U,$J,358.3,10044,2)
 ;;=Ectropion, Unspecified^38326
 ;;^UTILITY(U,$J,358.3,10045,0)
 ;;=374.14^^72^688^13
 ;;^UTILITY(U,$J,358.3,10045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10045,1,3,0)
 ;;=3^Ectropion, Cicatricial
